Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS

MICRO-MECHANICAL PUMP FOR NEXT GENERATION INSULIN DELIVERY SYSTEMS

Project description

Treating diabetes with a thin-film micropump

A revolutionary thin-film micropump, which can be used as an innovative system in wearable insulin delivery devices for the treatment of diabetes. That’s the EU-funded PRISMA technology. The integration of the PRISMA micropump in insulin patch pumps addresses the three most important challenges linked to this life-saving treatment: size, drug delivery accuracy and energy consumption. The project’s long-term goal is to allow the realisation of multi-drug delivery systems, making the multi-hormone treatment a reality. As for now, the main objective is to validate the pump and its manufacturing process in a real operating environment.

Objective

PRISMA is a revolutionary thin-film micropump realized with novel ceria-based oxides actuating materials in the frame of the FET-OPEN BioWings project, which can be used as an innovative pumping system in wearable insulin delivery devices for the treatment of diabetes. The integration of the PRISMA micropump in insulin patch pumps addresses the 3 most important pain points that still keep the vast majority of diabetic patients away from this life-saving treatment:
1) Size, which is more than two orders of magnitude smaller than state of the art.
2) Higher drug delivery accuracy within the ?5% range ensures the highest therapeutic efficacy.
3) drastic reduction in energy consumption.
Besides the short-term vision to realise extremely compact and accurate patch pumps, the long term goal is to allow the realisation of multi-drug delivery systems, making real the much-lauded multi-hormone treatment.
The main objective of this project is to validate the pump and its manufacturing process in a real operating environment, proving to system integrators that all specifications are consistently met to pave the way for the post-project system integration and clinical validation. This will pave the way to the launch of a startup company that will take care of the final steps of the development roadmap and will establish long-term cooperation agreements with prominent medical device manufacturers for the integration of PRISMA in next-generation single and multi-hormone smart patches.

Coordinator

DANMARKS TEKNISKE UNIVERSITET
Net EU contribution
€ 1 181 957,00
Address
ANKER ENGELUNDS VEJ 101
2800 Kongens Lyngby
Denmark

See on map

Region
Danmark Hovedstaden Københavns omegn
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 181 957,50

Participants (3)